ClinicalTrials.gg
RecruitingNCT06936176CREATEUpdated May 16, 2025

Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)

An interventional study of Neurovascular Intravascular Shockwave Catheter in Carotid Artery Stenosis, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Carotid Stenosis with a site in China — 33 open to participants now, 37 under way, 1 of them phase 3. Carotid Stenosis · China.

Planned enrollment
16th of 37
204 · median 178
Started
2025
with 7 others
No phase
26 of 71
13 open now
Primary completion
2027-12
later than 25 of 36 live
Registered
55th of 71
by date
Lead sponsor
2 of 71
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Among the 71 studies in Carotid Stenosis with a site in China, this one is the 16th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2025, is one of 26 with no phase, reaches primary completion later than 25 of the 36 other live ones, and was the 55th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

33 of the 71 studies in Carotid Stenosis with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carotid Stenosis with a site in China, or all of them as a file.
02

Study summary

  • Clinical Trial Summary

    • Trial Title:** CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions
    • Sponsor:** Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
    • Clinical Trial Leader:** Beijing Anzhen Hospital
    • Coordinating Investigator:** Prof. Huo Xiaochuan
  • Study Purpose This trial assesses a new device-a single-use neurovascular intravascular shockwave catheter and therapy device-for treating calcified blockages in the carotid artery. It uses sound waves to break up calcium deposits, facilitating stent placement and blood flow restoration.
  • Eligibility

    • Adults aged 18-80 with severe carotid artery narrowing (≥50% symptomatic or ≥70% asymptomatic) due to calcium buildup.
    • Patients who failed standard balloon dilation.
    • Exclusions include pregnancy, recent strokes/heart attacks, uncontrolled hypertension, or other high-risk conditions.
  • Study Design

    • **Type:** Prospective, multicenter, single-arm trial.
    • **Sample Size:** 204 patients across multiple hospitals.
    • **Duration:** 1-month follow-up post-procedure.
  • Procedures

    1. **Pre-treatment:** Imaging (CT angiography, ultrasound) to confirm eligibility.
    2. **Procedure:** Shockwave catheter breaks up calcium, followed by stent placement.
    3. **Follow-up:** Assessments at 7 days (or discharge) and 1 month post-procedure.
  • Benefits and Risks

    • **Benefits:** Improved stent placement success, reduced risk of complications, minimally invasive with shorter recovery time.
    • **Risks:** Bleeding, infection, vessel damage, stroke, heart attack, device malfunction. Risks are closely monitored with emergency protocols.
  • Patient Protections

    • Ethics committee approval and strict safety guidelines.
    • Voluntary participation with the option to withdraw anytime.
    • Free treatment and compensation for trial-related injuries.
  • For Healthcare Providers

    • **Innovation:** Adapts coronary lithotripsy technology for carotid use.
    • **Evidence:** Supported by preclinical data and a pilot study (100% success rate in 5 patients).
    • **Endpoints:** Primary: Stent success (residual stenosis \<30%) and 30-day major adverse events. Secondary: Device success rate, repeat procedures, long-term outcomes.
  • Contact Information

For questions, contact:

**Ms. Zhang Yanjiao** Email: yanjiao.zhang@jwmsgrp.com

Read the detailed description

**Detailed Clinical Trial Description**

### **1. Background and Rationale** **Clinical Need:**

  • **Carotid artery calcification** is a major contributor to ischemic stroke, accounting for 15-20% of cases. Severe calcification complicates stent placement, leading to high rates of residual stenosis and adverse events (e.g., stroke, myocardial infarction) with conventional treatments like balloon angioplasty.
  • **Current Limitations:** Standard therapies often fail to adequately modify calcified plaques, necessitating high-pressure balloon dilation, which risks embolization, vessel dissection, or hemodynamic instability.

**Innovative Solution:**

  • The **intravascular lithotripsy (IVL) system** delivers localized sonic pressure waves to fracture calcium deposits while sparing soft tissue, enabling safer stent deployment.
  • **Evidence Base:** Supported by coronary IVL trials (e.g., DISRUPT CAD I-IV) and off-label carotid case reports demonstrating 90-100% technical success with minimal complications.

    ### **2. Study Objectives** **Primary Objectives:**

  • **Efficacy:** Assess **surgical success rate** (stent placement with residual stenosis \<30%).
  • **Safety:** Evaluate **30-day major adverse events (MAE)** (composite of death, stroke, or myocardial infarction).

**Secondary Objectives:**

  • Device success rate (successful delivery/retrieval of IVL catheter).
  • Rates of target lesion revascularization, ipsilateral stroke, and MACCE (major adverse cardiac/cerebrovascular events).

    ### **3. Methodology** **Study Design:**

  • **Prospective, multicenter, single-arm, objective performance criteria (OPC) trial.**
  • **No control group** due to ethical concerns (standard therapy failure is an inclusion criterion).

**Intervention:**

  1. **IVL Catheter:** Rapid-exchange balloon catheter with integrated electrodes generating sonic waves (80 pulses max per device).
  2. **IVL Device:** Console delivering controlled energy pulses (compatible with 3.0-5.0 mm balloons).

**Procedure Steps:**

  • **Pre-treatment:** Dual antiplatelet therapy (aspirin + clopidogrel) for ≥3 days.
  • **IVL Delivery:**
  • Balloon inflation to 6 atm, followed by 10 pulses/cycle (up to 8 cycles).
  • Stent placement post-calcium modification.
  • **Post-procedure:** Monitoring for MAE at 7 days and 1 month.

**Key Assessments:**

  • **Imaging:** CT angiography (baseline), DSA (intraoperative), ultrasound (follow-up).
  • **Clinical:** NIHSS/mRS scores, vital signs, lab tests (hematology, biochemistry).

    • **4. Participant Selection** **Inclusion Criteria:**
  • Symptomatic (≥50%) or asymptomatic (≥70%) carotid stenosis with circumferential calcium >50% (CTA-confirmed).
  • Failed conventional balloon pre-dilation (residual stenosis >70%).
  • Modified Rankin Scale (mRS) score ≤2.

**Exclusion Criteria:**

  • Vulnerable plaques, recent stroke/MI (within 2-12 weeks), or contraindications to antiplatelets.
  • Severe comorbidities (e.g., NYHA Class IV heart failure, creatinine >2.5 mg/dL).

    ### **5. Risk Management** **Anticipated Risks:**

  • **Procedure-related:** Vessel dissection (1-3%), embolic stroke (2-5%), access-site hematoma.
  • **Device-related:** Balloon rupture, electrode malfunction (\<1%).

**Mitigation Strategies:**

  • **Embolic protection devices** mandatory.
  • **Strict operator training** (≥5 supervised cases required).
  • **Real-time monitoring** for hemodynamic instability (bradycardia/hypotension).

    ### **6. Statistical Plan** **Sample Size Justification:**

  • **Efficacy endpoint:** 107 patients needed (95% expected vs. 85% OPC, α=0.025, power=90%).
  • **Safety endpoint:** 204 patients (4.5% expected vs. 11% OPC).
  • **Total:** 204 (accounting for 10% dropout).

**Analysis Populations:**

  • **Full Analysis Set (FAS):** All treated patients (intent-to-treat).
  • **Per-Protocol Set (PPS):** Excludes major protocol deviations.

**Statistical Tests:**

  • Primary endpoints: **One-sided 95% CI** (success rate lower bound >85%; MAE upper bound \<11%).
  • Secondary endpoints: Descriptive statistics (rates, Kaplan-Meier survival analysis).

    ### **7. Ethical and Regulatory Compliance**

  • **Ethics Approval:** Obtained from all site IRBs (reference: LFBY-202501).
  • **Informed Consent:** Mandatory, with provisions for legally authorized representatives.
  • **Data Protection:** Compliant with China's Personal Information Protection Law (PIPL).

    ### **8. Operational Oversight**

  • **Monitoring:** Centralized EDC (Medidata Rave) with 100% source data verification.
  • **Audits:** Independent DSMB reviews safety data biannually.
03

Conditions studied

  • Carotid Artery Stenosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years (inclusive), gender unrestricted.
  2. Extracranial carotid artery: Preoperative CT angiography (CTA) confirms symptomatic carotid stenosis ≥50% or asymptomatic carotid stenosis ≥70% with calcification (CTA measurement: calcification > 50% of circumference).

    Note: (Extracranial carotid artery: Internal carotid artery or carotid bifurcation; Symptomatic refers to having had a non-disabling ischemic stroke or within 6 months.)

  3. Intraoperative digital subtraction angiography (DSA) confirms carotid stenosis ≥50% (by NASCET criteria) or asymptomatic carotid stenosis ≥70% (by NASCET criteria).
  4. Participants with a pre-enrollment modified Rankin Scale (mRS) score ≤2.
  5. Participants planned for carotid artery stenting (CAS) who have failed conventional balloon dilation.
  6. Patients or their legal guardians understand the purpose of the trial, provide , and agree to follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Target lesion caused by non-atherosclerotic disease.
  2. Participants with complete occlusion of the target lesion or contralateral carotid artery.
  3. Participants with severe disability due to cerebral infarction.
  4. Participants with large acute or subacute thrombi near the target lesion, or with arteriovenous malformations or aneurysms.
  5. Participants with tortuous target lesion vessels that prevent stent placement.
  6. Participants with symptomatic severe stenosis in other cerebral vessels.
  7. Participants requiring concurrent or additional surgical interventions during the trial period.
  8. Participants with tandem severe stenosis or occlusion in vessels proximal or distal to the target lesion.
  9. Participants who have had a myocardial infarction or large cerebral infarction within 2 weeks prior to screening.
  10. Participants who have had intracranial hemorrhage within 3 months prior to screening.
  11. Participants with vulnerable or high-risk plaques (unstable, prone to rupture, and thrombosis leading to acute cardiovascular events or death) as judged by carotid ultrasound.
  12. Participants with uncontrolled hypertension (systolic blood pressure persistently ≥180 mmHg or diastolic blood pressure persistently ≥110 mmHg).
  13. Participants with known count \< 90×10\^9/L, severe liver impairment (transaminases > 3 times the ), severe renal impairment (serum creatinine > 2.5 mg/dL [221 µmol/L]), or Class IV heart failure.
  14. Participants with coagulopathy ( ≥2.0) or to heparin or antiplatelet agents.
  15. Participants with active infections.
  16. Participants unable to use cerebral protection devices.
  17. Participants allergic to components of the device or contrast agents (excluding rash).
  18. Participants with less than 1 year.
  19. Pregnant or breastfeeding women.
  20. Participants currently enrolled in another drug or medical device clinical trial (before reaching the primary endpoint).
  21. Other situations where the investigator deems the participant unsuitable for the trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Patients with calcified extracranial carotid artery stenosis

    Study Arm: Single-arm, prospective, multicenter trial evaluating the safety and efficacy of the Neurovascular Intravascular Shockwave Catheter and Intravascular Shockwave Therapy Device for pretreatment of calcified lesions in the extracranial carotid artery prior to carotid artery stenting (CAS).

    Device: Neurovascular Intravascular Shockwave Catheter

Interventions

  • DeviceNeurovascular Intravascular Shockwave Catheter

    Device: Neurovascular Intravascular Shockwave Catheter (single-use, rapid-exchange balloon catheter with integrated shockwave emitters). Intravascular Shockwave Therapy Device (IVL-HVG-N01, generates localized shockwaves to fracture calcifications). Procedure: Patients undergo standard CAS preparation with guidewire placement and cerebral protection. If conventional balloon angioplasty fails (residual stenosis \>70%), the IVL catheter is advanced to the target lesion. Shockwave therapy is applied at 6 atm, followed by low-pressure balloon dilation (8 atm) if needed. Subsequent stent deployment is performed per standard practice.

06

What researchers measure

Primary outcomes

  1. Procedural Success Rate

    Successful stent deployment with residual stenosis \<30% after the procedure (via angiography).

    Time frame: Immediately post-procedure (intraoperative).

  2. 30-Day Major Adverse Events (MAE) Rate

    Composite of: All-cause death; Stroke (ischemic or hemorrhagic, with neurological deficits lasting ≥24h); Myocardial infarction (MI) (per standard diagnostic criteria).

    Time frame: 30 days (±7 days) post-procedure.

Secondary outcomes

  1. Device Success

    Successful delivery, activation, and retrieval of the neurovascular intravascular shockwave (IVL) catheter without technical failure.

    Time frame: Intraoperative

  2. Device Malfunction Rate

    The Device Malfunction Rate is the percentage of procedures where the IVL catheter or device fails to operate as intended, including issues like balloon rupture or electrode malfunction.

    Time frame: Intraoperative

  3. Target Lesion Revascularization Rate

    The incidence of revascularization treatment for the initially treated lesion vessel after surgery.

    Time frame: Within 7 days/Before Discharge, 1 Month Postoperative

  4. Ipsilateral Stroke Rate

    The occurrence of a stroke event on the same side as the target vessel in the subject.

    Time frame: Within 7 days/Before Discharge, 1 Month Postoperative

  5. Major Adverse Cardio-Cerebrovascular Events (MACCE) Rate

    A composite of all-cause death, any stroke, any myocardial infarction, and any revascularization.

    Time frame: Within 7 days/Before Discharge, 1 Month Postoperative

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 62 interventional studies with no phase under Carotid Stenosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2025
First posted
Apr 20, 2025
StartActual
May 12, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06936176
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
May 12, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion